ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BPCR Biopharma Credit Plc

0.87
-0.026 (-2.90%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Biopharma Credit Plc LSE:BPCR London Ordinary Share GB00BDGKMY29 ORD USD0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.026 -2.90% 0.87 0.87 0.874 0.886 0.87 0.886 4,461,524 16:35:03
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 218.17M 182.31M 0.1400 5.11 932.72M

BioPharma Credit PLC Notice of Full Year Results (2017D)

17/02/2020 10:10am

UK Regulatory


Biopharma Credit (LSE:BPCR)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Biopharma Credit Charts.

TIDMBPCR

RNS Number : 2017D

BioPharma Credit PLC

17 February 2020

17 February 2020

BIOPHARMA CREDIT PLC

(the "Company")

NOTICE OF FULL YEAR RESULTS

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, will announce its audited Full Year Results for the period ending 31 December 2019 on Tuesday 10 March 2020.

A management presentation will be delivered at 2:00pm GMT through a conference call facility, to request conference call details, RSVP to henryw@buchanan.uk.com .

-Ends-

Enquiries

BioPharma Credit PLC

via Link Company Matters Limited

Company Secretary

+44 (0) 1392 477 500

Buchanan

+44 (0)20 7466 5000

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORGPURUPUPUGUM

(END) Dow Jones Newswires

February 17, 2020 05:10 ET (10:10 GMT)

1 Year Biopharma Credit Chart

1 Year Biopharma Credit Chart

1 Month Biopharma Credit Chart

1 Month Biopharma Credit Chart

Your Recent History

Delayed Upgrade Clock